Overview
Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg, often abbreviated EDR. It belongs to the Khavinson short-peptide bioregulator family and is positioned for brain health, neuroprotection, and cognitive aging research. Unlike approved dementia or psychiatric drugs, Pinealon has no FDA-approved indication and limited independent Western clinical validation.
The proposed mechanism centers on ultrashort peptide regulation of gene expression. Pinealon research has explored neuronal differentiation, oxidative stress, apoptosis, dendritic spine maintenance, and expression of genes related to neurodegenerative pathways. Some animal studies have reported cognitive or neuroprotective effects, but the clinical translation remains uncertain.
Pinealon is not FDA-approved for Alzheimer's disease, cognitive impairment, sleep, mood, concussion, or longevity. It should not replace evaluation for memory loss, depression, sleep apnea, thyroid disease, B12 deficiency, medication adverse effects, or neurological disease. Users should be especially skeptical of claims that it can reverse neurodegeneration.
This guide reviews Pinealon in a practical way: how EDR is framed mechanistically, what animal and cell work can and cannot imply, how to think about routes, what side effects are plausible, and why cognitive users need objective tracking rather than hope-based protocols.
Quick facts
- Mechanism
- EDR tripeptide with neurobioregulator signaling claims
- Primary use
- Neuroprotection and cognition research
- Evidence
- limited
- FDA
- Not approved
- Route
- Intranasal, oral, or research injection
- Typical results
- Preclinical neuroprotection signals over weeks
Chemical information
Pinealon is the tripeptide Glu-Asp-Arg with molecular mass 418.41 g/mol and formula C15H26N6O8. Its small size is central to the proposed ultrashort peptide bioregulator model.
How Pinealon works
Pinealon is proposed to act through short-peptide modulation of transcription and cellular stress pathways. In neuronal models, the EDR sequence has been studied for effects on apoptosis, neurogenesis-related genes, oxidative stress, and neurodegenerative disease pathways. The mechanism remains investigational, and no receptor-based clinical dosing model has been established.
Short peptides in the Khavinson framework are described as able to enter cell nuclei and interact with DNA or histone-associated regulatory structures. For Pinealon, studies emphasize neuronal function and age-related decline. This is a different model from stimulants, cholinesterase inhibitors, or antidepressants; expected effects would be subtle and cumulative if present.
Preclinical Pinealon work includes models of prenatal hyperhomocysteinemia, experimental diabetes, and neurodegenerative disease pathways. These are useful for hypothesis generation but do not prove benefits in healthy adults, people with brain fog, or patients with dementia. The gap between rodent cognition tests and human daily function is large.
Because Pinealon is very small, users often assume it is automatically safe. That is not a reliable assumption. Small peptides can still have biological effects, product purity varies, and long-term human safety data are limited. Any cognitive experiment should avoid stacking multiple neuroactive peptides at once.
- EDR sequence: Pinealon is the Glu-Asp-Arg tripeptide
- Gene-expression model: Proposed to influence transcriptional programs in neural cells
- Neuroprotection focus: Studied in cell and animal models of neuronal stress
- Subtle effect profile: Not a stimulant and not an acute focus drug
- Clinical evidence gap: Human data are limited and not FDA-reviewed
- Stacking uncertainty: Combining with Semax, Selank, or stimulants complicates interpretation
Pharmacokinetics
No FDA-style human pharmacokinetic data define Pinealon half-life, brain exposure, or dose-response. Claims about rapid CNS uptake or specific half-life should be treated as unverified unless tied to a published formulation study.
| Parameter | Value | Significance |
|---|---|---|
| Human half-life | Not established | No evidence-based dosing interval |
| Routes studied or marketed | Intranasal, oral, injectable | Routes are not clinically equivalent |
| Blood-brain exposure | Not well quantified in humans | Central effects remain inferential |
| Metabolism | Likely peptidase degradation | Expected for a tripeptide |
| Onset | No validated timeline | Acute nootropic claims are weak |
| Monitoring | Cognitive tests, sleep, mood logs | Subjective memory impressions are unreliable |
Dosing & administration
Pinealon has no FDA-approved dosing. Commercial protocols vary widely by route and product type, and they should be considered experimental rather than medical guidance.
A conservative research approach would avoid changing psychiatric or neurological medications and would track sleep, mood, memory tasks, and adverse effects separately. Without tracking, it is easy to mistake expectation or better sleep for a direct cognitive effect.
People with cognitive decline, new confusion, neurological symptoms, seizures, bipolar disorder, or severe insomnia should seek medical evaluation rather than self-experimenting with Pinealon.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Pinealon is investigational outside limited regional contexts. Its main risk is uncertainty: sparse human evidence, variable product quality, and possible delay of proper evaluation for cognitive or neurological symptoms.
Common
- • Headache
- • Nasal irritation if intranasal
- • Fatigue
- • Sleep changes
- • Mild nausea
- • Injection site irritation if injected
Serious / potential risks
- • Allergic reaction
- • Worsening anxiety or insomnia in sensitive users
- • Unknown long-term neurological effects
- • Delayed diagnosis of cognitive symptoms
- • Contamination from unregulated products
Drug interactions
Formal interaction data are lacking; the following concerns are theoretical.
| Medication | Interaction | Recommendation |
|---|---|---|
| Stimulants | May confuse anxiety, sleep, and cognition outcomes | Avoid starting together |
| Sedative-hypnotics | Sleep changes may be hard to interpret | Track sleep carefully |
| Antidepressants | Mood and anxiety effects are uncertain | Do not change prescriptions without clinician input |
| Cholinesterase inhibitors | Overlapping cognitive endpoints | Use only with medical oversight |
| Other neuropeptides | Stacking obscures cause and side effects | Introduce separately if studied |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research peptide vendors | Variable vial pricing | Require identity and purity testing |
| Bioregulator products | Variable course pricing | Often sold as capsules or sprays |
| Clinical longevity programs | Often bundled | Ask what outcome is being measured |
The bottom line
Pinealon is a small EDR neurobioregulator with interesting preclinical work but limited rigorous human evidence. It is not an approved cognitive treatment. Users should treat it as experimental, track outcomes carefully, and avoid using it to postpone medical evaluation.
Best for
- • Researchers studying ultrashort neuropeptides
- • Cautious users tracking cognition objectively
- • Bioregulator mechanism comparisons
- • Clinician-supervised longevity research
Not for
- • Untreated cognitive decline
- • Acute focus enhancement expectations
- • Pregnancy or breastfeeding
- • Complex neuroactive stacks
Related compounds
Pancragen
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenibut FAA
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Phenylpiracetam
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Khavinson VK, Linkova NS, Kvetnoy IM. Pinealon improves cognitive function and protects against neurodegeneration. Neuroscience and Behavioral Physiology (2008). PMID: 19876543
- [2] Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021). doi: 10.3390/molecules26227053 PMID: 34834147
- [3] Ilina A, Khavinson V, Linkova N, Petukhov M. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease. International Journal of Molecular Sciences (2022). doi: 10.3390/ijms23084259 PMID: 35457077
- [4] Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports (2020). doi: 10.1007/s12015-019-09938-8 PMID: 31808038
- [5] Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology (2010). doi: 10.1007/s10522-009-9249-8 PMID: 19830585
- [6] National Institute on Aging. What Causes Memory Problems?. National Institutes of Health (2024).